(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news begins with adjusted ...

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier.

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...